publication date: Mar. 31, 2015

Study Shows 73% Survival at Three Years by Combining Radiation Therapy and Chemotherapy


Clinical-trial findings suggested that combining chemotherapy with radiation therapy is the best treatment for people with a low-grade form of brain cancer.

The phase II study shows that patients with low-grade gliomas at high risk for tumor recurrence have an overall survival of 73 percent after three years when treated with radiation plus temozolomide. This is compared with a three-year survival of 54 percent for historical controls treated with radiation alone.

The findings were published in the International Journal of Radiation Oncology, Biology, Physics.

“The most effective treatment for these rare tumors is currently controversial at best,” says Arnab Chakravarti, chair and professor of radiation oncology and co-director of the Brain Tumor Program at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. Chakravarti is the trial’s translational research national study chair.

“Our study reports that combining radiation with temozolomide-based chemotherapy appears to improve clinical outcome compared to historical controls treated by radiation alone. This may prove critical in killing enough tumor cells to prevent progression to stage IV disease, or glioblastoma multiforme, over time.”

The study also included researchers at the University of Maryland and at London Regional Cancer Program in Ontario, Canada.

Low-grade gliomas represent less than one percent of tumors in the U.S. The average survival times vary depending on the tumor’s structural, molecular and genetic features.

In the study, three-year progression-free survival rate was 59 percent. Grade 3 adverse events occurred in 43 percent of patients, and grade 4 events occurred in 10 percent of … Continue reading CCL March – Study Shows 73% Survival at Three Years by Combining Radiation Therapy and Chemotherapy

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.